RAPA-501 is under clinical development by Rapa Therapeutics and currently in Phase III for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase III drugs for Amyotrophic Lateral Sclerosis have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how RAPA-501’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RAPA-501 overview
RAPA-50 is under development for the treatment of amyotrophic lateral sclerosis (ALS). It is administered through parenteral route of administration. The therapeutic candidate comprises of autologous hybrid regulatory T lymphocytes.
it was under development for the treatment of Coronavirus disease 2019 (COVID-19.
Rapa Therapeutics overview
Rapa Therapeutics is a pharmaceutical and healthcare company. The company provides therapies for oncology disease. Rapa Therapeutics is headquartered in Rockville, Maryland, the US.
For a complete picture of RAPA-501’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.